PROBANT
follow us
// monograph
· #001

BPC-157

L-glutamyl-L-prolyl-L-prolyl-L-prolyl-glycyl-L-lysyl-L-prolyl-L-alanyl-L-aspartyl-L-aspartyl-L-alanyl-glycyl-L-leucyl-L-valine

pentadecapeptide·MW 1419.55·CAS 137525-51-0·monograph #001
VERIFIED

// 01 · identification

common name
BPC-157
iupac name
L-glutamyl-L-prolyl-L-prolyl-L-prolyl-glycyl-L-lysyl-L-prolyl-L-alanyl-L-aspartyl-L-aspartyl-L-alanyl-glycyl-L-leucyl-L-valine
sequence
GEPPPGKPADDAGLV
molecular formula
C62H98N16O22
molecular weight
1419.55
cas number
137525-51-0
pubchem cid

// 02 · pharmacology

mechanism of action
partial sequence of body protection compound isolated from gastric juice. modulates nitric oxide synthesis, upregulates growth hormone receptor expression in injured tissues, and accelerates angiogenesis through VEGFR2 pathway activation. demonstrates cytoprotective effects across gastrointestinal, musculoskeletal, and neural tissues in preclinical models.
half-life
30 min iv, 4–6 hr sc
bioavailability
limited oral, ~65% sc
routes
oral, subcutaneous, intramuscular

// 03 · clinical evidence

pubmed citations
top citations
clinicaltrials.gov
—
fda status
not regulated · research use only

// 04 · risk profile

side effects
  • •mild injection site reactions
  • •transient headache
  • •theoretical angiogenesis concerns
contraindications
  • •pregnancy and lactation
  • •active malignancy
  • •pediatric population
regulatory class
research chemical · banned by WADA

// 05 · on-chain reference

primary token
recent activity

// 06 · provenance

authored by
probant.curator.01
last reviewed
4mo ago
sources
on-chain signature
5KKsW8mZ…cDeFgHi2signed by probant.signer.7xK4…zn4P
monograph #001 · published May 01, 2026 · last updated May 04, 2026

probant is an open-data registry. monographs are curated references — not medical advice, not regulatory guidance.